Concepedia

Author

Stevan Shaw

UCB Pharma (United Kingdom)ORCID

Also Known As

S H Shaw, S Shaw, S. H. Shaw, S. SHAW, S. Shaw, Sabina Schacher, Sonia Shaw, Stevan Shaw

63

Publications

2.1K

Citations

24

H-Index

61

Concepts

All Affiliations

UCB Pharma (United Kingdom)UCB Pharma (Belgium)National Institute of Environmental Health SciencesUniversity of AmsterdamUniversity of Oxford
SS

About

Stevan Shaw is an author at UCB Pharma (United Kingdom) specializing in medicine, immunology, and autoimmune disease.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

11

12

541

2

Allergy

4

4

247

3

Health Sciences

2

2

126

4

Social Sciences

1

1

35

5

Biomolecular Engineering

1

1

84

Stevan Shaw

×

32

Publications

2K

Citations

24

H-Index

YearCitations

Dual IL-17A and IL-17F neutralisation by bimekizumab in psoriatic arthritis: evidence from preclinical experiments and a randomised placebo-controlled clinical trial that IL-17F contributes to human chronic tissue inflammation

Sophie Glatt, Dominique Baeten, Terry Baker,

Annals of the Rheumatic Diseases

2017

249

Bimekizumab, a Novel Humanized IgG1 Antibody That Neutralizes Both IL-17A and IL-17F

Ralph Adams, Asher Maroof, Terry Baker,

Frontiers in Immunology

2020

179

Efficacy and Safety of Bimekizumab in Moderate to Severe Hidradenitis Suppurativa

Sophie Glatt, Gregor B. E. Jemec, Seth Forman,

JAMA Dermatology

2021

158

First‐in‐human randomized study of bimekizumab, a humanized monoclonal antibody and selective dual inhibitor of IL‐17A and IL‐17F, in mild psoriasis

Sophie Glatt, Eric Helmer, Birgit Haier,

British Journal of Clinical Pharmacology

2016

140

Interleukin-6 Contributes to Inflammation and Remodeling in a Model of Adenosine Mediated Lung Injury

Mesias Pedroza, Daniel J. Schneider, Harry Karmouty‐Quintana,

PLoS ONE

2011

120

Generation and characterization of a high affinity anti-human FcRn antibody, rozanolixizumab, and the effects of different molecular formats on the reduction of plasma IgG concentration

Bryan Smith, Rocío Lledó‐García, Kate L. Dixon,

mAbs

2018

110

CDP7657, an anti-CD40L antibody lacking an Fc domain, inhibits CD40L-dependent immune responses without thrombotic complications: an in vivo study

Anthony Shock, Linda C. Burkly, Ian Wakefield,

Arthritis Research & Therapy

2015

102

Discovery and characterization of olokizumab

Stevan Shaw, Tim Bourne, Chris Meier,

mAbs

2014

84

Radial-arm maze deficits produced by colchicine administered into the area of the nucleus basalis are ameliorated by cholinergic agents

Hugh A. Tilson, Ronnie L. McLamb, Stevan Shaw,

Brain Research

1988

80

A Double-Blind, Comparative Study of Zolpidem and Placebo in the Treatment of Insomnia in Elderly Psychiatric In-Patients

Stevan Shaw, H Curson, J P Coquelin

Journal of International Medical Research

1992

75

Page 1